Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Supernus Pharm (SUPN)

Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Supernus Pharmaceuticals' CEO to Speak at 36th Annual Piper Sandler Healthcare Conference

Supernus Pharmaceuticals' CEO will speak at the Piper Sandler Healthcare Conference on December 4, 2024.Quiver AI SummarySupernus Pharmaceuticals, Inc. announced that President and CEO Jack A. Khattar...

SUPN : 35.59 (+0.45%)
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

SUPN : 35.59 (+0.45%)
Supernus Pharmaceuticals' CEO Jack Khattar to Speak at Jefferies London Healthcare Conference on November 20, 2024

Supernus Pharmaceuticals announced CEO Jack Khattar will participate in a fireside chat at the Jefferies London Healthcare Conference.Quiver AI SummarySupernus Pharmaceuticals, Inc. announced that its...

SUPN : 35.59 (+0.45%)
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference

SUPN : 35.59 (+0.45%)
Supernus: Q3 Earnings Snapshot

Supernus: Q3 Earnings Snapshot

SUPN : 35.59 (+0.45%)
Supernus Announces Third Quarter 2024 Financial Results

SUPN : 35.59 (+0.45%)
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

SUPN : 35.59 (+0.45%)
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results

SUPN : 35.59 (+0.45%)
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder

SUPN : 35.59 (+0.45%)
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder

SUPN : 35.59 (+0.45%)

Barchart Exclusives

3 Pharma Stocks to Buy as California Sounds the Alarm on Bird Flu Cases
The bird flu crisis is creating investment opportunities in the pharmaceutical sector, with Sanofi, GSK, and CSL Limited emerging as top picks. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar